Novavax appoints vice president of manufacturing

Mervyn Hamer takes responsibility for manufacturing at Rockville and Gaithersburg plants

US vaccine manufacturer Novavax has appointed Mervyn Hamer as vice president of manufacturing. He takes responsibility for manufacturing at the biopharmaceutical firm’s Rockville and Gaithersburg, MD, US locations, with oversight of materials management, clinical manufacturing, facilities, environmental, health & safety and security.

Prior to joining Novavax, Hamer was vice president of supply chain management and engineering at Intercell USA and vice president of operations at Iomai Corporation, its predecessor company. Before joining Iomai, he was technical director at PATH.

Prior to PATH, he worked at Alza Corporation for nine years, where he led the establishment of a commercial manufacturing facility in Vacaville, CA for a variety of controlled release dosage forms and became director of manufacturing.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Novavax vaccine candidate produces immune response against deadly virus

Study by University of Maryland School of Medicine highlights potential effective means for preventing MERS-CoV
Research & Development

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities
Manufacturing

Novavax signs long-term lease on vaccine plant

Will relocate corporate hq to same campus in Gaithersburg
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Research & Development

Novavax RSV vaccine ‘safe and well tolerated’

Firm ready to advance towards human clinical trials
Subscribe now